Surfactant Protein Genetic Variants in COVID-19 Infection

Study Overview
=================
Brief Summary
-----------------
Surfactant protein plays important role in innate immunity against respiratory viral infections. However, investigators have shown that the surfactant protein polymorphisms are associated with severity of various pulmonary diseases such as respiratory syncytial virus (RSV), tuberculosis, pediatric acute lung injury. COVID-19 virus gains entry through the respiratory system and responsible for death due to acute respiratory failure. There is a considerable heterogeneity in presentation of COVID-19 infection from asymptomatic patients to severe infection requiring intensive care and some may die. Considering reports of COVID-19 related deaths/severe disease in the same family, it is possible that genetics play an important role in severity of COVID-19 infection. Investigators propose to study the association of surfactant proteins in COVID-19 patients. Key Objectives: a) Characterize genetic markers within the surfactant protein genes in COVID-19 positive patients, b) To determine if there is a correlation between certain genetic markers and the severity of COVID-19 infection which may be used as a prognostic marker, c) To correlate genetic markers with immune studies.

Official Title
-----------------
Surfactant Protein Genetic Variants in COVID-19 Infection

Conditions
-----------------
Coronavirus Infection

Intervention / Treatment
-----------------
* Other: Identification of genetic variants


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: The major inclusion criteria is a confirmed diagnosis of COVID-19 infection performed on nasopharyngeal secretions by enzyme immunoassay or culture in patients. Exclusion Criteria: Patients unable to sign informed consent will be excluded.

Ages Eligible for Study
-----------------
Minimum Age: 1 Day
Maximum Age: 90 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Mild COVID-19 infection<br>Patients with confirmed COVID-19 infection who remained asymptomatic and/or never hospitalized. | Other: Identification of genetic variants<br>* DNA will be extracted from whole blood from study subjects<br>|
| Moderate COVID-19 infection<br>Patients with confirmed COVID-19 infection who got admitted in general ward in the hospital. | Other: Identification of genetic variants<br>* DNA will be extracted from whole blood from study subjects<br>|
| Severe COVID-19 infection<br>Patients with confirmed COVID-19 infection who got admitted in intensive care unit and/or did not survive. | Other: Identification of genetic variants<br>* DNA will be extracted from whole blood from study subjects<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Correlation of surfactant protein genetic variants with severity of COVID-19 infection |  | 12 months |